Topics
Gliomas | Treatment | Targeted therapy | Tovorafenib
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > Tovorafenib
Optic pathway glioma
Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E,
Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson
AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S,
McCowage G, Hansford JR, Khuong-Quang DA, Gottardo NG, Hassall T,
Han JW, Yalon Oren M, Chi SN, Qiu J, Da Costa D, Govinda Raju S,
Manley P, Hargrave D.
Radiographic and
visual response to the type II RAF inhibitor tovorafenib in
children with relapsed/refractory optic pathway glioma in the
FIREFLY-1 trial.
Neuro
Oncol. 2024 Dec 19:noae274. doi:
10.1093/neuonc/noae274. PMID:
39700439. Observational study. ˍ